Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic...

Area of Science:

• Hematology
• Oncology
• Molecular Pathology

Background:

• Diffuse large B-cell lymphoma (DLBCL) classification into molecular subgroups (germinal center B-cell like and activated B-cell like) via gene expression profiling (GEP) has prognostic significance.
• GEP is costly and not routinely applicable in clinical practice, necessitating surrogate methods.

Purpose of the Study:

• To develop and validate an immunohistochemical (IHC) algorithm as a cost-effective surrogate for GEP in classifying DLBCL molecular subgroups.
• To assess the prognostic value of the developed IHC algorithm in DLBCL patients treated with rituximab-CHOP chemotherapy.

Main Methods:

• Tissue microarrays from 475 de novo DLBCL patients treated with rituximab-CHOP were analyzed.
• Immunohistochemistry was performed using antibodies for CD10, GCET1, FOXP1, MUM1, and BCL6.
• An algorithm based on CD10, FOXP1, and BCL6 expression was developed and validated against GEP results.

Main Results:

• The developed IHC algorithm demonstrated 92.6% concordance with GEP classification.
• The algorithm showed a simpler structure compared to previously proposed IHC algorithms.
• Both the International Prognostic Index and the proposed IHC algorithm were significant independent predictors of progression-free and overall survival.

Conclusions:

• The developed IHC algorithm effectively classifies DLBCL molecular subgroups and predicts patient prognosis.
• This algorithm offers a practical and cost-effective alternative to GEP for routine clinical use in the era of rituximab therapy.